{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"condition":["Colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/103018"],"study_start_month":["4"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"GR study","description":"Interventions: Share the result of Guardant Reveal test with the patient;ctDNA\nPrimary outcome(s): This is defined as the percentage of patients whose recommended treatment changed before and after the initial Guardant Reveal test in the FAS. Thisis defined as the percentage of patients for whom the recommended treatment was changed before or after the initial Guardant Reveal test.\nA change in recommended therapy is defined as at least one of the following\nAddition or deletion of oxaliplatin\nChange in the use of postoperative adjuvant therapy\nChange in duration of adjuvant therapy.\nStudy Design: single arm study, open(masking not used), uncontrolled control, single assignment, health services research","dates":{"creation":"2023-04-15"},"accession":"103018","cross_references":{"Japan Primary Registries Network":["JPRN-jRCTs032220652"]}}